Ladon Therapeutics launches DrugSol® - the first-of-its-kind foldamer-based compound library – the launchpad for next generation therapeutics.

‍

DrugSol® is redefining Drug Discovery with Drug-Like Foldamers.

It is a novel application of ourA3SMO® - Artificial Amino Acid-based Small Molecules Platform. It is designed to bridge the gap between peptide complexity and small molecule drug-likeness.

‍

DrugSol® is unique.

Unlike conventional peptide libraries, our platform is built on artificial amino acids and foldamer backbones (β-, γ-, and peptoid-based). It offers:

- Stable, protease-resistant scaffolds;

- Membrane-permeable, cell-penetrating architectures;

- Rich conformational diversity for untapped target spaces and

- Drug-like properties by design.

‍

DrugSol® provides streamlined hit identification.

Every compound in the library can be fully characterized with integrated:

- Physicochemical profiles;

- Cell uptake and bioactivity data and

- Functional readouts in inflammation & fibrosis models (gene expression profiling and in vivo disease models).

- This enables unparalleled rapid hits triaging and efficient structure–activity relationship development.

‍

DrugSol® is green &scalable.

Using continuous-flow synthesis and green chemistry principles, we ensure sustainable and scalable production —ready for screening, conjugation, or direct therapeutic exploration.

‍

DrugSol® is the launchpad for the next generation of therapeutics.

If you are working in:

- Drug discovery, chemical biology, peptide therapeutics or protein-protein interaction modification;

- Key indications such as Inflammatory Bowel Disease(IBD), Cystic Fibrosis, Pulmonary Fibrosis;

this platform is for you!

‍

For further information and customer registration please visit us at https://drugsol.ladon.life

‍